InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration
Portfolio Pulse from
InMed Pharmaceuticals Inc. has announced the selection of an intravitreal formulation for their drug candidate INM-089, aimed at treating dry age-related macular degeneration. The formulation has shown successful delivery at doses up to 10 times the projected therapeutic level, indicating a favorable pharmacokinetic profile and significant safety margin.
February 03, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
InMed Pharmaceuticals has advanced its INM-089 drug candidate for dry AMD treatment, showing promising pharmacokinetic and safety results in dose-ranging studies.
The announcement of successful delivery and a favorable safety profile for INM-089 in treating dry AMD is a positive development for InMed Pharmaceuticals. This progress in their drug pipeline could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100